In late 2019, Gustav Eyler, the Director of the U.S. Department of Justice’s (“DOJ”) Consumer Protection Branch (“CPB”), cited fraudulent data in clinical research trials for new drugs and medical devices as a topic of “major...more
3/23/2021
/ Clinical Laboratory Testing ,
Clinical Trials ,
Coronavirus/COVID-19 ,
Corruption ,
Criminal Prosecution ,
Department of Justice (DOJ) ,
Enforcement ,
False Statements ,
Food and Drug Administration (FDA) ,
Fraud ,
Medical Devices ,
Medical Research ,
Pharmaceutical Industry ,
Popular ,
Willful Misconduct ,
Wire Fraud
The National Defense Authorization Act for FY 2021 (“NDAA”) passed Congress on December 11, 2020, with a “veto-proof” margin. Included within the NDAA are a number of anti-money laundering provisions with import for companies...more
12/17/2020
/ Anti-Money Laundering ,
Corruption ,
Disclosure ,
Disclosure Requirements ,
FinCEN ,
Foreign Banks ,
Foreign Corporations ,
Foreign Corrupt Practices Act (FCPA) ,
Limited Liability Company (LLC) ,
NDAA ,
Reporting Requirements ,
U.S. Treasury ,
Whistleblowers